Clinical Trials Directory

Trials / Unknown

UnknownNCT04625257

COVID-19 in Baselland: Validation of Simple and Accurate Tests for COVID-19 Detection, Monitoring and Tracing (ACCURATE-BL-COVID-19)

Status
Unknown
Phase
Study type
Observational
Enrollment
1,600 (estimated)
Sponsor
University Hospital, Basel, Switzerland · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study is to establish an accurate, robust and easily scalable COVID-19 viral nucleic acid analysis platform from, but not limited to, saliva to help enable and support contact tracing in the canton of Baselland/ Switzerland. To achieve this, crude ribonucleotide acid (RNA) extraction from saliva is validated in combination with next-generation sequencing (NGS) diagnostics and loop mediated amplification (LAMP) assays as well as point of care test (POCT) for rapid detection of viral antigens on patients' samples.

Conditions

Interventions

TypeNameDescription
OTHERSaliva based assay: crude RNA extractionCrude RNA extraction to inactivate the virus and stabilize the RNA for transport at room temperature. Validation of the crude RNA extraction from saliva in combination with NGS diagnostics and LAMP assays and point of care test (POCT) for rapid detection of viral antigens on patients' samples.
OTHERValidation of the NGS methodCompare the results obtained with the next-generation sequencing (NGS) method to the nasopharyngeal swabs analysed in a FAMH certified lab.
OTHERValidation of the LAMP assaysThe RNA will be analyzed onsite using the loop mediated amplification (LAMP) assay.
OTHERValidation of the POCT Antigen and Antibody testsRapid point of care tests (POCT) detecting viral protein antigens (Ag) and antibodies (Ab) on patients' samples. POCT are often employed in low income countries, but for COVID-19 they are not yet characterized. Their performance is to be characterized that they can be used as a safe guard if the lab diagnostics fail.

Timeline

Start date
2020-10-24
Primary completion
2024-12-01
Completion
2024-12-01
First posted
2020-11-12
Last updated
2024-02-23

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT04625257. Inclusion in this directory is not an endorsement.